Ovctek China, Inc. Class A

Ovctek China, Inc. Class A

SSZSE:300595
10.23
CNY
-0.04
(-0.39%)
0.55EPS
20.63P/E
9.09BMarket Cap
Mar 29Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.14
0.21
0.28
0.37
0.37
0.54
0.76
1.03
1.53
1.75
1.94
2.03
2.08
2.03
Basic EPS, GAAP
0.04
0.1
0.14
0.18
0.18
0.26
0.36
0.51
0.65
0.72
0.75
0.64
0.54
0.49
Free Cash Flow per Basic Share
0.08
0.09
0.1
0.13
0.1
0.13
0.26
0.34
0.58
0.6
0.59
0.54
0.68
- -
Dividend per Share
0.02
0.03
0.01
0.12
0.03
0.03
0.04
0.05
0.15
0.14
0.14
0.23
0.29
0.19
Book Value per Share
0.23
0.3
0.4
0.49
0.94
1.19
1.55
2.04
2.61
4.73
4.85
5.24
5.49
5.81
Tangible Book Value per Share
0.23
0.3
0.39
0.48
0.93
1.13
1.44
1.83
2.28
4.36
4.23
4.52
4.41
4.74
Basic Weighted Avg Shares
632
632
632
634
836
845
853
843
849
871
893
893
893
894
Sales/Revenue/Turnover
91
130
176
235
312
458
647
871
1,295
1,525
1,737
1,814
1,861
1,817
Operating Margin (%)
32.27
51.94
54.01
53.12
53.45
48.18
46.03
49.1
47.3
46.59
43.62
39.48
35.16
33.22
Depreciation Expense
2
2
3
4
5
9
17
27
82
100
109
136
161
- -
Net Income, GAAP
25
64
89
114
151
216
307
433
555
624
667
572
480
440
Effective Tax Rate (%)
25.64
16.6
16.03
16.26
16.95
14.69
11.69
3.92
13.49
12.4
13.94
14.58
15.42
15.7
Profit Margin (%)
27.25
49.1
50.33
48.52
48.41
47.17
47.44
49.77
42.84
40.9
38.37
31.55
25.77
24.24
Working Capital
112
159
208
233
678
859
1,075
1,394
1,600
3,423
3,110
3,142
3,138
3,458
LT Debt
- -
- -
- -
- -
- -
- -
- -
123
115
151
172
185
147
120
Total Equity
146
192
254
316
812
1,082
1,438
1,991
2,536
4,596
4,711
5,144
5,409
5,620
Return on Invested Capital (%)
18.33
34.56
37.16
37.73
25.94
21.84
23.16
25.25
24.18
18.44
14.98
12.12
9.9
- -
Return on Capital (%)
19.75
38.24
40.03
40.12
27.14
23.51
25.33
23.59
21.38
14.66
12.53
10.27
7.68
- -
Return on Common Equity (%)
19.75
37.9
40.04
40.44
27.02
23.65
26.07
28.12
27.96
19.36
15.54
12.65
9.98
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
87
87
75
LT Borrowings
- -
10
10
LT Finance Leases
133
118
110
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
895
895
894
Market Capitalization
12,650
9,427
9,087

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
4,050
3,776
4,024
Cash, Cash Equivalents & STI
2,376
2,186
2,512
Accounts Receivable, Net
288
280
287
Inventories
176
167
170
Total Current Liabilities
694
514
566
Payables & Accruals
- -
- -
- -
ST Debt
87
87
75
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
41.17%
25.08%
5.16%
Free Cash Flow
28.52%
19.39%
27.39%
Net Income, GAAP
20.43%
3.39%
-16.2%
Sales/Revenue/Turnover
27.62%
17.49%
2.62%
Total Cash Common Dividend
109.3%
58.34%
25.29%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
465
419
548
383
1,814
2025
478
392
- -
428
1,861
2026
459
406
523
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.22
0.15
0.22
0.06
0.64
2025
0.18
0.1
- -
0.04
0.54
2026
0.16
0.1
0.19
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.22
- -
- -
0.23
2025
- -
0.22
- -
0.06
0.29
2026
- -
0.13
- -
- -
- -

Company Description

CEO
Yue Qun Tao
Full Time Employees
3,752
Sector
Health technology
Industry
Medical specialties
Address
No. 4899 Wangjiang West Road Hefei AN China 230088
IPO Date
Jan 17, 2017
Website
orthok.cn
Business
Autek China Inc. is a high-tech enterprise specializing in eye health and myopia prevention and control technology and services. The company's core products include orthokeratology lenses, general contact lenses, contact lens care products, and other eye health products. Its main product line features the "Dream David" series of corneal reshaping lenses designed to correct vision and slow the progression of myopia. In addition to manufacturing, Autek China provides ophthalmic and optometry medical devices as well as a range of optometry services, including the operation of eye care hospitals. The company focuses on integrated, personalized optometry services catering to customers across all age groups primarily in the domestic Chinese market. Founded in 2000, Autek China is headquartered in Hefei, China. Recent strategic developments include the company's acquisition of a 75% equity stake in Suqian Shangyue Qicheng Hospital Management Co., Ltd., reflecting its expansion into hospital management and eye care service networks. Autek has also initiated production and deliveries of contact lenses from Jiangsu Duozi Medical and continues the promotion of its DK185 orthokeratology lens with increasing market adoption. Despite some performance pressures noted in the first half of 2025, including a slight revenue decline and reduced net profit, the company is actively investing in expanding its service terminals and product innovation. It operates through its Ophthalmology Services and Products segments and maintains a strong presence in China with ambitions for broader service integration. Autek's industry focus spans medical equipment, eye care and optometry services, and ophthalmic device manufacturing. It holds recognized trademarks such as the “Dream David” series and has received accolades including the Anhui Pharmaceutical Quality Management Award and the Hefei Science and Technology Giant honor. The company utilizes both direct retail sales and strategic partnerships within China, underpinning its solid market position in the eye health sector. In summary, Autek China Inc. offers a comprehensive suite of eye health products and services focused on vision correction and myopia control. Recent acquisitions and product launches illustrate its strategic shift towards enhancing both product offerings and healthcare service operations within China’s ophthalmology market, maintaining its commitment to technological innovation and integrated optometry solutions.